Review Article
TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
Table 3
MINORS quality evaluation for included uncontrolled studies.
| Study | Clear purpose | Patient continuity | Data collection | Appropriate endpoint | Objective evaluation endpoint | Adequate follow-up time | Low lost to follow-up rate | Sample size estimation | Total score |
| Cicero et al. 2020 [24] | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 0 | 12 | Cecchini et al. 2021 [25] | 2 | 2 | 2 | 2 | 1 | 2 | 0 | 0 | 11 | Sforza et al. 2017 [26] | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | 13 | Montes et al. 2020 [27] | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 0 | 12 | Takahashi et al. 2021 [28] | 2 | 2 | 1 | 2 | 1 | 2 | 1 | 0 | 11 | Kwakman et al. 2018 [29] | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 13 | Moehler et al. 2021 [30] | 2 | 2 | 1 | 2 | 1 | 1 | 2 | 0 | 11 | Yoshida et al. 2020 [31] | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 15 | Wallander et al. 2020 [32] | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | 13 | Satake et al. 2020 [33] | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 15 | Carries et al. 2019 [34] | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 0 | 12 |
|
|